Durata Therapeutics

Durata Therapeutics is a clinical development stage pharmaceutical company. Read more

Paul Edick's photo - CEO of Durata Therapeutics

CEO

Paul Edick

CEO Approval Rating

70/100

Founded:

01/2009

Status:

Out Of Business

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Durata Therapeutics?

Durata Therapeutics Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$10.1M

Durata Therapeutics Acquisitions

No recent acquisitions found related to Durata Therapeutics

Durata Therapeutics Funding History

Since Durata Therapeutics was founded in 01/2009, it has participated in 1 round of funding. In total Durata Therapeutics has raised $67.5M. Durata Therapeutics' funding round was on Jul 2012 for a total of $67.5M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jul 2012
$67.5M

Since Durata Therapeutics was founded in 01/2009, it has participated in 1 round of funding. In total Durata Therapeutics has raised $67.5M. Durata Therapeutics' funding round was on Jul 2012 for a total of $67.5M

Durata Therapeutics Investments

No recent investments found related to Durata Therapeutics

Durata Therapeutics News

March 4, 20154-TRADERS

Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan

(4-traders.com) DUBLIN, March 2, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it... See more »
March 4, 20154-TRADERS

Actavis Receives Approval from the European Commission for XYDALBA (dalbavancin)

(4-traders.com) - Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults... See more »
February 25, 20154-TRADERS

Actavis Receives Final Approval for Generic Version of Subutex�

(4-traders.com) DUBLIN, Feb. 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it... See more »
January 13, 20154-TRADERS

Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings

(4-traders.com) DUBLIN and IRVINE, Calif., Jan. 12, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) and ... See more »
January 13, 20154-TRADERS

Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA� IR

(4-traders.com) DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the... See more »
January 6, 20154-TRADERS

Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension

(4-traders.com) DUBLIN, Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that th... See more »
December 24, 20144-TRADERS

Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference

(4-traders.com) DUBLIN, Dec. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global speci... See more »

Durata Therapeutics Blogs

Durata Therapeutics Press Releases

October 31, 2014PR NEWSWIRE

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata

DUBLIN and CHICAGO, Oct. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Durata Therapeutics, In... See more »
October 11, 2014BUSINESS WIRE

Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company

BALA CYNWYD, Pa.--(BUSINESS WIRE)--Law office of Brodsky & Smith, LLC announces that it is investigat... See more »
October 7, 2014PRLOG

Actavis will buy Durata Therapeutics, Inc in a deal worth $675 million

Actavis will acquire Durata's novel antibiotic DALVANCE - the first and only IV antibiotic approved f... See more »
October 6, 2014BUSINESS WIRE

Glancy Binkow & Goldberg LLP is Investigating Durata Therapeutics, Inc. Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP is investigating potential claims against ... See more »
October 6, 2014BUSINESS WIRE

Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Actavis

DALLAS--(BUSINESS WIRE)--DURATA THERAPEUTICS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe an... See more »

Social Media

Durata Therapeutics Headquarters

200 S Wacker Dr Suite 2550

Chicago, Illinois60606

312-219-7000

Driving Directions »

Trending Companies

Durata Therapeutics Summary

ABOUT

Overview

Durata Therapeutics is a clinical development stage pharmaceutical company. Durata Therapeutics was founded in 01/2009. Durata Therapeutics' headquarters is located in Chicago, Illinois, USA 60606. It has raised 67.5M in 1 round. The latest round was ...

CEO

Durata Therapeutics's CEO, Paul Edick, currently has an approval rating of 70%. Durata Therapeutics's primary competitors are

Frequently Asked Questions about Durata Therapeutics

  1. When was Durata Therapeutics founded?

    Durata Therapeutics was founded in 01/2009
  2. Who is Durata Therapeutics's CEO?

    Durata Therapeutics's CEO is Paul Edick
  3. How much revenue does Durata Therapeutics generate?

    Durata Therapeutics generates $10.1M in revenue
  1. How much funding does Durata Therapeutics have?

    Durata Therapeutics has historically raised $67.5M in funding
  2. Where is Durata Therapeutics's headquarters?

    Durata Therapeutics's headquarters is in Chicago Illinois, USA
  3. How many employees does Durata Therapeutics have?

    Durata Therapeutics has 67 employees